Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 29.15 USD -0.61%
Market Cap: 4.7B USD
Have any thoughts about
Alkermes Plc?
Write Note

Operating Margin
Alkermes Plc

29%
Current
6%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
29%
=
Operating Profit
436.5m
/
Revenue
1.5B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
IE
Alkermes Plc
NASDAQ:ALKS
4.7B USD
29%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
316.8B USD
28%
US
Amgen Inc
NASDAQ:AMGN
145.1B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
113.2B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.7B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.3B EUR
-22%
Country IE
Market Cap 4.7B USD
Operating Margin
29%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 316.8B USD
Operating Margin
28%
Country US
Market Cap 145.1B USD
Operating Margin
19%
Country US
Market Cap 119B USD
Operating Margin
40%
Country US
Market Cap 113.2B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.4B AUD
Operating Margin
26%
Country US
Market Cap 82.7B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.3B EUR
Operating Margin
-22%
No Stocks Found

Alkermes Plc
Glance View

Market Cap
4.7B USD
Industry
Biotechnology

Alkermes Plc is a global biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 2,211 full-time employees. The firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The company has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The firm's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The firm's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

ALKS Intrinsic Value
28.79 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
29%
=
Operating Profit
436.5m
/
Revenue
1.5B
What is the Operating Margin of Alkermes Plc?

Based on Alkermes Plc's most recent financial statements, the company has Operating Margin of 29%.